This poster is published under an
open license. Please read the
disclaimer for further details.
Type:
Educational Exhibit
Keywords:
Toxicity, Drugs / Reactions, Complications, Chemotherapy, CT-High Resolution, Conventional radiography, Thorax, Respiratory system, Lung
Authors:
D. Giri, S. Gupta, P. Rao, D. Barnes; Leicester/UK
DOI:
10.1594/ecr2016/C-1865
Conclusion
Drug-induced interstitial lung disease is a potentially life-threatening condition and the radiologist has a key role to play in early diagnosis by raising the possibility,
defining the various DILD patterns,
ruling out other differential diagnosis and aid the clinician in monitoring treatment response.
There are no pathognomonic imaging features of DILD.
Following new drug therapy,
the presence of either new diffuse alveolar damage,
hypersensitivity pneumonitis,
non-specific interstitial pneumonia,
organising pneumonia or fibrosis (in chronic disease) favours the diagnosis of DILD.
Improvement of these imaging findings and clinical symptoms on drug cessation most likely favours the diagnosis of DILD.
Recurrence of symptoms and imaging findings on reintroduction of the drug increases specificity further. HRCT is currently the best non-invasive diagnostic imaging modality for assessment of DILD and correlates well with the histological pattern of lung parenchymal damage.